Patents by Inventor Yongxin Han

Yongxin Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EP4 Receptor Agonist, Compositions and Methods Thereof
    Publication number: 20110237511
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: June 3, 2011
    Publication date: September 29, 2011
    Applicant: Merck Frosst Canada
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • Quinoline derivatives as EP4 antagonists
    Patent number: 8013159
    Abstract: The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R5) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: September 6, 2011
    Assignee: Merck Canada Inc.
    Inventors: Michel Belley, Jason Burch, John Colucci, Julie Farand, Mario Girard, Yongxin Han
  • Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
    Patent number: 8003661
    Abstract: The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: August 23, 2011
    Assignee: Merck Canada Inc.
    Inventors: Jason Burch, Julie Farand, Yongxin Han, Claudio Sturino
  • AKT PROTEIN KINASE INHIBITORS
    Publication number: 20100168123
    Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: September 25, 2009
    Publication date: July 1, 2010
    Inventors: Ian S. Mitchell, Keith L. Spencer, Peter Stengel, Yongxin Han, Nicholas C. Kallan, Mark Munson, Guy P.A. Vigers, James Blake, Anthony Piscopio, John Josey, Scott Miller, Dengming Xiao, Rui Xu, Chang Rao, Bing Wang, April L. Bernacki
  • PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
    Publication number: 20100152219
    Abstract: Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    Type: Application
    Filed: February 25, 2010
    Publication date: June 17, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Michael Howard Block, John W. Lee, David Scott, Haixia Wang, Tao Wang, Dingwei Yu, Yongxin Han, John Anthony Josey, Bin Wang
  • NAPHTHALENE AND QUINOLINE SULFONYLUREA DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
    Publication number: 20100105718
    Abstract: The invention is directed to naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: March 25, 2008
    Publication date: April 29, 2010
    Applicant: MERCK FROSST CANADA LTD.
    Inventors: Jason Burch, Julie Farand, Yongxin Han, Claudio Sturino
  • FUSED AROMATIC PTP-1B INHIBITORS
    Publication number: 20100022477
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.
    Type: Application
    Filed: January 24, 2008
    Publication date: January 28, 2010
    Inventors: John Colucci, Marie-Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K. Lau, Christopher Bayly
  • INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
    Publication number: 20090318518
    Abstract: The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: February 22, 2008
    Publication date: December 24, 2009
    Inventors: Michael Boyd, John Colucci, Yongxin Han
  • Chemical compounds
    Patent number: 7622482
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: November 24, 2009
    Assignee: AstraZeneca
    Inventors: Yongxin Han, Michelle Lamb, Peter Mohr, Bin Wang, Tao Wang, Dingwei Yu
  • EP4 Receptor Agonist, Compositions and Methods Thereof
    Publication number: 20090270395
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. The compounds of the present invention are the compounds of Formula (I).
    Type: Application
    Filed: July 28, 2006
    Publication date: October 29, 2009
    Inventors: John Colucci, Yongxin Han, Julie A. Farand
  • EP4 receptor agonist, compositions and methods thereof
    Publication number: 20090258918
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient.
    Type: Application
    Filed: June 10, 2009
    Publication date: October 15, 2009
    Inventors: Xavier Billot, Robert N. Young, Yongxin Han
  • THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS
    Publication number: 20090247596
    Abstract: The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II).
    Type: Application
    Filed: August 10, 2007
    Publication date: October 1, 2009
    Inventors: Marc Blouin, Jason Burch, Yongxin Han, Christophe Mellon
  • Chemical Compounds
    Publication number: 20090137624
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: February 15, 2006
    Publication date: May 28, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Michelle Lamb, Tao Wang, Dingwel Yu, Yongxin Han, Peter Mohr, Bin Wang
  • EP4 Receptor Agonist, Compositions and Methods Thereof
    Publication number: 20090105234
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: July 28, 2006
    Publication date: April 23, 2009
    Inventors: John Colucci, Yongxin Han, Julie A. Farand
  • Quinoline derivatives as ep4 antagonists
    Publication number: 20090099226
    Abstract: The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom, a N(O) group or a C(R5) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.
    Type: Application
    Filed: May 15, 2006
    Publication date: April 16, 2009
    Inventors: Michel Belley, Jason Burch, John Colucci, Julie Farand, Mario Girard, Yongxin Han
  • Materials and methods to potentiate cancer treatment
    Publication number: 20080090782
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Application
    Filed: February 16, 2007
    Publication date: April 17, 2008
    Applicant: Luitpold Pharmaceuticals, Inc.
    Inventors: James Halbrook, Edward Kesicki, Laurence Burgess, Stephen Schlachter, Charles Eary, Justin Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • EPreceptor agonist, compositions and methods thereof
    Patent number: 7238710
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: July 3, 2007
    Assignee: Merck Frosst Canada, Ltd.
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • Pyrazole derivatives as inhibitors of receptor tyrosone kinases
    Publication number: 20070142413
    Abstract: Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    Type: Application
    Filed: November 15, 2004
    Publication date: June 21, 2007
    Inventors: Michael Block, John Lee, David Scott, Haixia Wang, Tao Wang, Dingwei Yu, Yongxin Han, John Josey, Bin Wang
  • Materials and methods to potentiate cancer treatment
    Patent number: 7179912
    Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: February 20, 2007
    Assignee: ICOS Corporation
    Inventors: James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G. Schiro, Hongmei Huang, Michael Evans, Yongxin Han
  • EPreceptor agonist, compositions and methods thereof
    Patent number: RE42562
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: July 19, 2011
    Assignee: Merck Frosst Canada
    Inventors: Xavier Billot, John Colucci, Robert N. Young, Yongxin Han, Marie-Claire Wilson